Immuneering Corporation

NASDAQ:IMRX

Biotechnology

Healthcare
$3.50 -0.14%

-$0.01 today

Market cap
$226.67M
Beta
0.38
P/E (TTM)
-3.6
EPS (TTM)
-$1.24
52W Low $2.29High $10.08

Volume 0.73M

Average 1.38M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$59.38M

FY 2025 · Annual

Net Income

-$56.02M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.08M316.95K000
Cost of Revenue1.15M158.12K00698.89K
Gross Profit926.89K158.83K00(698.89K)
Gross Margin44.6%50.1%———
Research & Development26.54M36.27M41.62M47.96M42.05M
Selling, General & Admin8.27M15.61M16.76M16.08M17.3M
Operating Expenses34.81M51.9M58.41M64.07M58.68M
Depreciation & Amortization159.07K277.25K352.08K385.07K698.89K
EBITDA(33.68M)(51.47M)(58.06M)(63.69M)(55.33M)
EBITDA Margin-1619.5%-16238.4%———
Operating Income(33.89M)(51.74M)(58.41M)(64.07M)(59.38M)
Operating Margin-1629.2%-16325.8%———
Interest Income169.9K1.01M3.61M2.59M3.04M
Interest Expense00000
Other Income / Expenses42.83K1.23M4.94M3.03M3.35M
Income Before Tax(33.84M)(50.51M)(53.47M)(61.04M)(56.02M)
Pre-Tax Margin-1627.1%-15937.4%———
Income Tax Expense(307.49K)0000
Net Income(33.54M)(50.51M)(53.47M)(61.04M)(56.02M)
Net Margin-1612.3%-15937.3%———
EPS (Basic)(1.27)(1.87)(1.88)(2.04)(1.27)
EPS (Diluted)(1.27)(1.87)(1.88)(2.04)(1.27)
Weighted Avg Shares26.32M26.39M28.42M29.98M44.01M
Weighted Avg Shares (Diluted)26.32M26.39M28.42M29.98M44.01M

IMRX Earnings Waterfall · TTM

NASDAQ:IMRX · Revenue to Net Income

Key Ratios

EPS$-1.17
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-4.3
P/S Ratio0.0

Analysis

$0 of revenue converted into -$54.4M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.17, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 9, 2026
4Statement of changes in beneficial ownershipNov 9, 2026
3Initial statement of beneficial ownershipNov 9, 2026
10-QQuarterly reportOct 29, 2026
8-KCurrent reportOct 29, 2026

How much revenue does IMRX generate?

Immuneering Corporation (IMRX) reported $0.00 of revenue in fiscal 2025.

Is IMRX profitable?

Immuneering Corporation (IMRX) reported -$56.02M of net income.